Liquid Biopsy Market by Biomarkers, Sample, Type, Technology, Indication, End-User, Application

List of Tables

The Liquid Biopsy Market was valued at USD 6.00 billion in 2023, expected to reach USD 6.72 billion in 2024, and is projected to grow at a CAGR of 12.19%, to USD 13.44 billion by 2030.

Liquid biopsy is a rapidly growing diagnostic technology that involves analyzing non-solid biological tissues, primarily blood, to detect cancer and other conditions. The technique identifies circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers, offering a non-invasive alternative to traditional tissue biopsies. The necessity of liquid biopsy is underscored by its potential for early cancer detection, monitoring tumor dynamics, guiding treatment decisions, and overcoming the limitations of tissue biopsy, such as accessibility and feasibility. Its applications extend to oncology, non-invasive prenatal testing (NIPT), and transplant monitoring, while end-use spans hospitals, research laboratories, and academic institutions.

KEY MARKET STATISTICS
Base Year [2023]	USD 6.00 billion
Estimated Year [2024]	USD 6.72 billion
Forecast Year [2030]	USD 13.44 billion
CAGR (%)	12.19%

Key market growth factors include technological advancements, increasing cancer prevalence, and growing awareness of personalized medicine. The latest opportunities lie in expanding applications in real-time cancer monitoring and precision oncology, addressing the high unmet need for non-invasive diagnostic tools. Companies can strategize by investing in research to improve detection sensitivity and specificity, and by forming partnerships with healthcare providers to accelerate adoption. Challenges in the liquid biopsy market include regulatory hurdles, high costs, and technical issues related to the accuracy and standardization of tests. The potential for false positives/negatives also poses a significant barrier.

Innovative areas ripe for exploration include enhancing bioinformatics tools to better analyze complex genomic data, improving assay technologies for broader biomarker capture, and developing point-of-care testing solutions. The liquid biopsy market is characterized by fierce competition, rapid scientific progression, and a strong inclination toward collaborative efforts for research and development. Firms engaging in strategic alliances and investing in robust clinical trials are more likely to succeed. In summary, while liquid biopsy offers compelling opportunities, its market growth is contingent upon overcoming technical and regulatory challenges, improving the cost-effectiveness of tests, and demonstrating clear clinical utility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Liquid Biopsy Market

The Liquid Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Rising incidence and prevalence of cancer
- Increasing preference for noninvasive diagnostic procedures
Market Restraints
- Low abundance and fragile nature of the circulating tumor cells (CTCs)
Market Opportunities
- Significant use of microarrays and next-generation sequencing (NGS)
- Availability of funding to expand cancer research in the field of liquid biopsy
Market Challenges
- Unclear regulatory and reimbursement scenario

Porter's Five Forces: A Strategic Tool for Navigating the Liquid Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Liquid Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Liquid Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Liquid Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Liquid Biopsy Market

A detailed market share analysis in the Liquid Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Liquid Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Liquid Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Liquid Biopsy Market

A strategic analysis of the Liquid Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include ANGLE PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocartis NV, CellMax Life, Inc., Danaher Corporation, DiaCarta, Inc., Dxcover Limited, Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Laboratory Dr. med. Pachmann, Lucence Health Inc., LungLife AI, Inc., MDxHealth SA, Menarini Silicon Biosystems SpA, Merck KGaA, Myriad Genetics, Inc., Natera, Inc., Neogenomics, Inc., OncoDNA SA, PerkinElmer, Inc., Personalis, Inc., QIAGEN N.V., SAGA Diagnostics AB, Strand Life Sciences Pvt Ltd., Sysmex Corporation, Tempus AI, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Biomarkers, market is studied across Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, and Extracellular Vesicles.
Based on Sample, market is studied across Blood Based and Urine Based.
Based on Type, market is studied across Assay Kits, Instruments, and Services.
Based on Technology, market is studied across Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays.
Based on Indication, market is studied across Cancer Indication and Non-Cancer Indication. The Cancer Indication is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer.
Based on End-User, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories.
Based on Application, market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-43470FC608C8

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising incidence and prevalence of cancer
  - 5.1.1.2. Increasing preference for noninvasive diagnostic procedures
- 5.1.2. Restraints
  - 5.1.2.1. Low abundance and fragile nature of the circulating tumor cells (CTCs)
- 5.1.3. Opportunities
  - 5.1.3.1. Significant use of microarrays and next-generation sequencing (NGS)
  - 5.1.3.2. Availability of funding to expand cancer research in the field of liquid biopsy
- 5.1.4. Challenges
  - 5.1.4.1. Unclear regulatory and reimbursement scenario
5.2. Market Segmentation Analysis
- 5.2.1. Biomarkers: Significant utilization of cell-free DNA (cfDNA) versatile in identifying genetic changes
- 5.2.2. Sample: Rising usage of blood-based liquid biopsies owing to their broad clinical applications and robust data support
- 5.2.3. Type: Evolving usage of assay kits for early detection and screening of cancer symptoms
- 5.2.4. Technology: Increasing preference for the multi-gene parallel analysis using next-generation sequencing (NGS), offering higher throughput data
- 5.2.5. Indication: Burgeoning preference for liquid biopsy tests for breast cancer due to its high prevalence
- 5.2.6. End-User: Proliferating usage of the liquid biopsy test across the clinical diagnostic laboratories
- 5.2.7. Application: Exponential utilization of the liquid biopsy for early cancer screening
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
5.5. Client Customization
- 5.5.1. Maintrac-based Treatment: Mraket size and forecast 2018-2030 (USD Million)

6. Liquid Biopsy Market, by Biomarkers

6.1. Introduction
6.2. Cell-free DNA
6.3. Circulating Tumor Cells
6.4. Circulating Tumor DNA
6.5. Extracellular Vesicles

7. Liquid Biopsy Market, by Sample

7.1. Introduction
7.2. Blood Based
7.3. Urine Based

8. Liquid Biopsy Market, by Type

8.1. Introduction
8.2. Assay Kits
8.3. Instruments
8.4. Services

9. Liquid Biopsy Market, by Technology

9.1. Introduction
9.2. Multi-gene Parallel Analysis using NGS
9.3. Single-gene Analysis using PCR Microarrays

10. Liquid Biopsy Market, by Indication

10.1. Introduction
10.2. Cancer Indication
- 10.2.1. Breast Cancer
- 10.2.2. Colorectal Cancer
- 10.2.3. Lung Cancer
- 10.2.4. Melanoma
- 10.2.5. Prostate Cancer
10.3. Non-Cancer Indication

11. Liquid Biopsy Market, by End-User

11.1. Introduction
11.2. Academic & Research Centers
11.3. Clinical Diagnostic Laboratories
11.4. Hospitals
11.5. Physician's Office Laboratories

12. Liquid Biopsy Market, by Application

12.1. Introduction
12.2. Early Cancer Screening
12.3. Recurrence Monitoring
12.4. Therapy Selection
12.5. Treatment Monitoring

13. Americas Liquid Biopsy Market

13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States

14. Asia-Pacific Liquid Biopsy Market

14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam

15. Europe, Middle East & Africa Liquid Biopsy Market

15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom

16. Competitive Landscape

16.1. Market Share Analysis, 2023
16.2. FPNV Positioning Matrix, 2023
16.3. Competitive Scenario Analysis
- 16.3.1. FDA Approves FoundationOne Liquid CDx for Targeted Treatment of Advanced Prostate Cancer
- 16.3.2. Labcorp Expands Precision Oncology Portfolio with New Liquid Biopsy Services, Strengthening Cancer Diagnostics and Patient Care
- 16.3.3. Personalis Inc. Launches Commercialized Cancer MRD Testing to Revolutionize Diagnostics with Advanced Genomic Technologies
- 16.3.4. Royal Marsden NHS Foundation Trust and Guardant Health Partner to Enhance Lung Cancer Detection and Treatment with Advanced Liquid Biopsy Tests
- 16.3.5. Florida Adopts DiaCarta's RadTox Test for Early Cancer Treatment Response, Advancing Statewide Patient Care
- 16.3.6. GediCube's Acquisition of Cyclomics to Boost Innovation and Market Reach in Liquid Biopsy Sector
- 16.3.7. Myriad Genetics Expands in Liquid Biopsy Market with Strategic Acquisition of Gateway Genomics
- 16.3.8. Veracyte Inc. Acquires C2i Genomics Ltd. to Elevate Cancer Detection with AI-Enhanced Liquid Biopsy Technology
- 16.3.9. Illumina Inc. Unveils Advanced Liquid Biopsy Assay for Enhanced Genomic Profiling and Personalized Cancer Treatment
- 16.3.10. UCLA Secures USD 4.6 Million to Innovate Liquid Biopsy Technology, Aiming for Enhanced Cancer Detection and Management
- 16.3.11. Innovative Blood Test by Delfi Diagnostics Aims to Enhance Lung Cancer Screening and Improve Patient Outcomes
- 16.3.12. Harbinger Health Raises USD 140M in Series B to Advance Early Cancer Detection with Liquid Biopsy Technology
16.4. Strategy Analysis & Recommendation
- 16.4.1. F. Hoffmann-La Roche Ltd.
- 16.4.2. Illumina Inc.
- 16.4.3. QIAGEN N.V.
- 16.4.4. Guardant Health, Inc.

Companies Mentioned

1. ANGLE PLC
2. Bio-Rad Laboratories, Inc.
3. Bio-Techne Corporation
4. Biocartis NV
5. CellMax Life, Inc.
6. Danaher Corporation
7. DiaCarta, Inc.
8. Dxcover Limited
9. Epic Sciences Inc.
10. Exact Sciences Corporation
11. F. Hoffmann-La Roche Ltd.
12. Guardant Health, Inc.
13. Illumina, Inc.
14. Laboratory Corporation of America Holdings
15. Laboratory Dr. med. Pachmann
16. Lucence Health Inc.
17. LungLife AI, Inc.
18. MDxHealth SA
19. Menarini Silicon Biosystems SpA
20. Merck KGaA
21. Myriad Genetics, Inc.
22. Natera, Inc.
23. Neogenomics, Inc.
24. OncoDNA SA
25. PerkinElmer, Inc.
26. Personalis, Inc.
27. QIAGEN N.V.
28. SAGA Diagnostics AB
29. Strand Life Sciences Pvt Ltd.
30. Sysmex Corporation
31. Tempus AI, Inc.
32. Thermo Fisher Scientific Inc.